Search is Powered by Google
Cancer / Oncology News

Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B

Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology;  Pediatrics / Children's Health
Article Date: 15 Nov 2006 - 17:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Consumer advocates and drug companies are debating FDA's decision to grant Barr Pharmaceuticals three years of regulatory exclusivity for its emergency contraceptive Plan B, which can prevent pregnancy if taken up to 72 hours after sexual intercourse, the Boston Globe reports. In exchange for exclusivity -- in which the drug will receive no generic competition for a certain period of time -- Barr must conduct a series of studies to determine how consumers use the product and how they understand the new label. Melissa Dunn, a spokesperson for GlaxoSmithKline Consumer Healthcare, said exclusivity provides "some incentive for innovation," adding, "It's really for companies who are doing all of the background research, investing the [research and development] dollars, and time and efforts into developing a product to give them some protection for a period of time." GSK received three years of exclusivity for over-the-counter sales of the smoking cessation drug Nicorette. Sidney Wolfe, director of the Health Research Group at Public Citizen, said the exclusivity means that consumers will have to pay more for the drug than they should, adding that pharmaceutical companies "should get some advantage for" their research, "but it seems like three years is on the long side." Democratic lawmakers, who will hold the majority in the 110th Congress, have said they will seek some restrictions in the methods drug makers use to keep generic competition off the market (Boston Globe, 11/13).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Nicorette.





Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Prostate Cancer Symptoms image Treating Prostate Cancer Symptoms

Many men will have advanced prostate cancer without any noticeable symptoms. Treatment for these patients is a bit different than for other patients with prostate cancer. Learn about these differences...

View more videos...